UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

31/10/2016 - 3 minutes

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco.

Sanofi_regeneronShould Sarilumab be approved, this immunotherapy will be used to treat sufferers of mild to severe Rheumatoid Arthritis – a debilitating and painful chronic disease. These phase III trial results are therefore great news, having succeeded in both co-primary endpoints: improvement in symptoms of Rheumatoid and improvement in physical function of patient joints.

There is a strong competition for antibody research into chronic auto-immune diseases such as Rheumatoid. A few Biotech giants are extra anxious to make new breakthroughs in the field, seeing as some of their Rheumatoid blockbuster patents will soon expire (i.e. AbbVie and Johnson&Johnson), exposing their sales territory to the merciless Biosimilar…


This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member